Trevi Therapeutics, Inc. - 8-K Filing
Trevi Therapeutics stockholders approved an increase in authorized common shares from 200 million to 400 million and amendments to its 2019 Stock Incentive Plan, including adding 8 million new shares for issuance. The changes were ratified at the June 3, 2026 annual meeting. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year At the Annual Meeting, the Company’s stockholders approved an amendm, 5.07 Submission of Matters to a Vote of Security Holders On June 3, 2026, the Company held the Annual Meeting, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $TRVI